[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100622094":3},{"organization":4,"outcomesModule":7,"designInfo":19,"detailedDescription":22,"studyPopulation":23,"armGroups":24,"interventions":11,"overallOfficials":11,"centralContacts":29,"locations":35,"responsibleParty":67,"collaborators":11,"id":69,"slug":70,"hasResults":71,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":75,"eligibilityCriteria":76,"healthyVolunteers":77,"sex":78,"minAge":79,"maxAge":80,"enrollmentInfo":81,"targetDuration":84,"studyType":85,"phases":11,"briefSummary":86,"conditions":87,"keywords":89,"overallStatus":38,"whyStopped":11,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":101},{"fullName":5,"class":6},"Serum Institute of India Pvt. Ltd.","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":11},[9],{"measure":10,"description":11,"timeFrame":12},"Geometric mean titers (GMTs) measured by rSBA against serogroups A, C, Y, W and X",null,"five-six years after vaccination.",[14,16],{"measure":15,"description":11,"timeFrame":12},"Percentage of participants with rSBA titers ≥ 8",{"measure":17,"description":11,"timeFrame":18},"Percentage of participants with rSBA titers ≥ 128","five-six years after vaccination",{"allocation":11,"interventionModel":11,"interventionModelDescription":11,"primaryPurpose":11,"observationalModel":20,"timePerspective":21,"maskingInfo":11},"COHORT","PROSPECTIVE","This non-interventional long-term follow-up study will involve one telephonic contact in all 1800 former participants from study ACYWX-03 followed by one visit beyond five years after vaccination in a subset of 450 participants. This subset will be randomly selected to participate in a follow-on immune persistence evaluation. To document the duration of the immune response and any requirement of booster dose in the target population, this study is intended to explore antibody persistence.","Participants from the previous study ACYWX-03 conducted at the Gambia and Mali",[25,27],{"label":26,"type":11,"description":11,"interventionNames":11},"NmCV-5",{"label":28,"type":11,"description":11,"interventionNames":11},"MenACWY-D",[30],{"name":31,"role":32,"phone":33,"phoneExt":11,"email":34},"Dr Prasad Kulkarni, MD, FRCP","CONTACT","+91-20-71946820","drpsk@seruminstitute.com",[36,53],{"facility":37,"status":38,"city":39,"state":11,"zip":11,"country":40,"countryCode":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":48},"Centre pour le Développement des Vaccins du Mali, ex-Institut Marchoux, Ministry of Health, BP251 Bamako, Mali BP251","RECRUITING","Bamako","Mali","ML",{"type":43,"coordinates":44},"Point",[45,46],-7.97522,12.60915,{"lat":46,"lon":45},[49],{"name":50,"role":32,"phone":51,"phoneExt":11,"email":52},"Samba Sow, MD, MSc","+223 20 23 6031","ssow@cvd-mali.org",{"facility":54,"status":38,"city":55,"state":11,"zip":11,"country":56,"countryCode":11,"cosmosGeoPoint":57,"geoPoint":61,"contacts":62},"Medical Research Council Unit The Gambia at the London School of Hygiene & Tropical Medicine, Fajara, The Gambia","Banjul","The Gambia",{"type":43,"coordinates":58},[59,60],-16.57803,13.45274,{"lat":60,"lon":59},[63],{"name":64,"role":32,"phone":65,"phoneExt":11,"email":66},"Dr. Olubukola Idoko, MB BS, MSc, PhD","+220 449 5443","Olubukola.Idoko@lshtm.ac.uk",{"type":68,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100622094","evaluation-of-the-antibody-persistence-beyond-five-years-after-immunization-with-menfivetm-nmcv-5-a-pentavalent-meningococcal-acywx-conjugate-vaccine-100622094",false,"NCT07379151","Evaluation of the Antibody Persistence Beyond Five Years After Immunization With MenFiveTM (NmCV-5), a Pentavalent Meningococcal ACYWX Conjugate Vaccine","Evaluation of the Antibody Persistence in African Participants Beyond Five Years After Immunization With MenFiveTM (NmCV-5), a Pentavalent Meningococcal ACYWX Conjugate Vaccine","PERS-ACYWX-03","Inclusion Criteria:\n\n* Written informed consent and assent (if applicable)\n\nExclusion Criteria:\n\n* Current or previous, confirmed disease caused by Neisseria meningitidis at any given time since meningococcal vaccination\n* Any condition or criteria that in the opinion of the investigator might compromise the well-being of the participant or the compliance with study procedures or interfere with the outcome of the study",true,"ALL","7 Years","36 Years",{"count":82,"type":83},450,"ESTIMATED","1 Day","OBSERVATIONAL","This study will measure immune persistence of the NmCV-5 more than 5 years after a single dose vaccination in participants 2-29 years of age in Mali and The Gambia.",[88],"Meningoccocal Disease",[90,91],"Seropersistence","Meningococcal","2026-05-29",{"date":94,"type":95},"2026-06-03","ACTUAL",{"date":97,"type":95},"2026-05-05",{"date":99,"type":83},"2026-12",{"name":5,"class":6},2]